Ponto, Claudia

[["dc.bibliographiccitation.firstpage","e125"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Neurology"],["dc.bibliographiccitation.lastpage","e134"],["dc.bibliographiccitation.volume","93"],["dc.contributor.author","Minikel, Eric Vallabh"],["dc.contributor.author","Vallabh, Sonia M."],["dc.contributor.author","Orseth, Margaret C."],["dc.contributor.author","Brandel, Jean-Philippe"],["dc.contributor.author","Haïk, Stéphane"],["dc.contributor.author","Laplanche, Jean-Louis"],["dc.contributor.author","Zerr, Inga"],["dc.contributor.author","Parchi, Piero"],["dc.contributor.author","Capellari, Sabina"],["dc.contributor.author","Safar, Jiri"],["dc.contributor.author","Kenny, Janna"],["dc.contributor.author","Fong, Jamie C."],["dc.contributor.author","Takada, Leonel T."],["dc.contributor.author","Ponto, Claudia"],["dc.contributor.author","Hermann, Peter"],["dc.contributor.author","Knipper, Tobias"],["dc.contributor.author","Stehmann, Christiane"],["dc.contributor.author","Kitamoto, Tetsuyuki"],["dc.contributor.author","Ae, Ryusuke"],["dc.contributor.author","Hamaguchi, Tsuyoshi"],["dc.contributor.author","Sanjo, Nobuo"],["dc.contributor.author","Tsukamoto, Tadashi"],["dc.contributor.author","Mizusawa, Hidehiro"],["dc.contributor.author","Collins, Steven J."],["dc.contributor.author","Chiesa, Roberto"],["dc.contributor.author","Roiter, Ignazio"],["dc.contributor.author","de Pedro-Cuesta, Jesús"],["dc.contributor.author","Calero, Miguel"],["dc.contributor.author","Geschwind, Michael D."],["dc.contributor.author","Yamada, Masahito"],["dc.contributor.author","Nakamura, Yosikazu"],["dc.contributor.author","Mead, Simon"],["dc.date.accessioned","2020-12-10T18:41:46Z"],["dc.date.available","2020-12-10T18:41:46Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1212/WNL.0000000000007745"],["dc.identifier.eissn","1526-632X"],["dc.identifier.issn","0028-3878"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77669"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Age at onset in genetic prion disease and the design of preventive clinical trials"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2004"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Neurobiology of Aging"],["dc.bibliographiccitation.lastpage","U20"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Lukic, Ana"],["dc.contributor.author","Uphill, James"],["dc.contributor.author","Brown, Craig A."],["dc.contributor.author","Beck, John"],["dc.contributor.author","Poulter, Mark"],["dc.contributor.author","Campbell, Tracy"],["dc.contributor.author","Adamson, Gary"],["dc.contributor.author","Hummerich, Holger"],["dc.contributor.author","Whitfield, Jerome"],["dc.contributor.author","Ponto, Claudia"],["dc.contributor.author","Zerr, Inga"],["dc.contributor.author","Lloyd, Sarah E."],["dc.contributor.author","Collinge, John"],["dc.contributor.author","Mead, Simon"],["dc.date.accessioned","2018-11-07T09:57:39Z"],["dc.date.available","2018-11-07T09:57:39Z"],["dc.date.issued","2015"],["dc.description.abstract","Prion diseases are a diverse group of neurodegenerative conditions, caused by the templated misfolding of prion protein. Aside from the strong genetic risk conferred by multiple variants of the prion protein gene (PRNP), several other variants have been suggested to confer risk in the most common type, sporadic Creutzfeldt-Jakob disease (sCJD) or in the acquired prion diseases. Large and rare copy number variants (CNVs) are known to confer risk in several related disorders including Alzheimer's disease (at APP), schizophrenia, epilepsy, mental retardation, and autism. Here, we report the first genome-wide analysis for CNV-associated risk using data derived from a recent international collaborative association study in sCJD (n = 1147 after quality control) and publicly available controls (n = 5427). We also investigated UK patients with variant Creutzfeldt-Jakob disease (n = 114) and elderly women from the Eastern Highlands of Papua New Guinea who proved highly resistant to the epidemic prion disease kuru, who were compared with healthy young Fore population controls (n = 395). There were no statistically significant alterations in the burden of CNVs >100, >500, or >1000 kb, duplications, or deletions in any disease group or geographic region. After correction for multiple testing, no statistically significant associations were found. A UK blood service control sample showed a duplication CNV that overlapped PRNP, but these were not found in prion disease. Heterozygous deletions of a 30 region of the PARK2 gene were found in 3 sCJD patients and no controls (p = 0.001, uncorrected). A cell-based prion infection assay did not provide supportive evidence for a role for PARK2 in prion disease susceptibility. These data are consistent with a modest impact of CNVs on risk of late-onset neurologic conditions and suggest that, unlike APP, PRNP duplication is not a causal high-risk mutation. (C) 2015 Elsevier Inc. All rights reserved."],["dc.identifier.doi","10.1016/j.neurobiolaging.2015.01.011"],["dc.identifier.isi","000355100900021"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37209"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","1558-1497"],["dc.relation.issn","0197-4580"],["dc.title","Rare structural genetic variation in human prion diseases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","371"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","The American Journal of Human Genetics"],["dc.bibliographiccitation.lastpage","382"],["dc.bibliographiccitation.volume","95"],["dc.contributor.author","Minikel, Eric Vallabh"],["dc.contributor.author","Zerr, Inga"],["dc.contributor.author","Collins, Steven J."],["dc.contributor.author","Ponto, Claudia"],["dc.contributor.author","Boyd, Alison"],["dc.contributor.author","Klug, Genevieve M. J. A."],["dc.contributor.author","Karch, Andre"],["dc.contributor.author","Kenny, Joanna"],["dc.contributor.author","Collinge, John"],["dc.contributor.author","Takada, Leonel T."],["dc.contributor.author","Forner, Sven"],["dc.contributor.author","Fong, Jamie C."],["dc.contributor.author","Mead, Simon"],["dc.contributor.author","Geschwind, Michael D."],["dc.date.accessioned","2018-11-07T09:33:47Z"],["dc.date.available","2018-11-07T09:33:47Z"],["dc.date.issued","2014"],["dc.description.abstract","Anticipation is the phenomenon whereby age of onset in genetic disease decreases in successive generations. Three independent reports have claimed anticipation in Creutzfeldt-Jakob disease (CJD) caused by the c.598G>A mutation in PRNP encoding a p.Glu200Lys (E200K) substitution in the prion protein. If confirmed, this finding would carry clear implications for genetic counseling. We analyzed pedigrees with this mutation from four prion centers worldwide (n = 217 individuals with the mutation) to analyze age of onset and death in affected and censored individuals. We show through simulation that selective ascertainment of individuals whose onset falls within the historical window since the mutation's 1989 discovery is sufficient to create robust false signals both of anticipation and of heritability of age of onset. In our data set, the number of years of anticipation observed depends upon how strictly the data are limited by the ascertainment window. Among individuals whose disease was directly observed at a study center, a 28-year difference between parent and child age of onset is observed (p = 0.002), but including individuals ascertained retrospectively through family history reduces this figure to 7 years (p = 0.005). Applying survival analysis to the most thoroughly ascertained subset of data eliminates the signal of anticipation. Moreover, even non-CJD deaths exhibit 16 years anticipation (p = 0.002), indicating that ascertainment bias can entirely explain observed anticipation. We suggest that reports of anticipation in genetic prion disease are driven entirely by ascertainment bias. Guidelines for future studies claiming statistical evidence for anticipation are suggested."],["dc.identifier.doi","10.1016/j.ajhg.2014.09.003"],["dc.identifier.isi","000342654300003"],["dc.identifier.pmid","25279981"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32045"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Cell Press"],["dc.relation.issn","1537-6605"],["dc.relation.issn","0002-9297"],["dc.title","Ascertainment Bias Causes False Signal of Anticipation in Genetic Prion Disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","602"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Alzheimer s & Dementia"],["dc.bibliographiccitation.lastpage","608"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Slattery, Catherine F."],["dc.contributor.author","Beck, Jonathan A."],["dc.contributor.author","Harper, Lorna"],["dc.contributor.author","Adamson, Gary"],["dc.contributor.author","Abdi, Zeinab"],["dc.contributor.author","Uphill, James"],["dc.contributor.author","Campbell, Tracy"],["dc.contributor.author","Druyeh, Ron"],["dc.contributor.author","Mahoney, Colin J."],["dc.contributor.author","Rohrer, Jonathan D."],["dc.contributor.author","Kenny, Janna"],["dc.contributor.author","Lowe, Jessica"],["dc.contributor.author","Leung, Kelvin K."],["dc.contributor.author","Barnes, Josephine"],["dc.contributor.author","Clegg, Shona L."],["dc.contributor.author","Blair, Melanie"],["dc.contributor.author","Nicholas, Jennifer M."],["dc.contributor.author","Guerreiro, Rita J."],["dc.contributor.author","Rowe, James B."],["dc.contributor.author","Ponto, Claudia"],["dc.contributor.author","Zerr, Inga"],["dc.contributor.author","Kretzschmar, Hans A."],["dc.contributor.author","Gambetti, Pierluigi"],["dc.contributor.author","Crutch, Sebastian J."],["dc.contributor.author","Warren, Jason D."],["dc.contributor.author","Rossor, Martin N."],["dc.contributor.author","Fox, Nick C."],["dc.contributor.author","Collinge, John"],["dc.contributor.author","Schott, Jonathan M."],["dc.contributor.author","Mead, Simon"],["dc.date.accessioned","2018-11-07T09:32:52Z"],["dc.date.available","2018-11-07T09:32:52Z"],["dc.date.issued","2014"],["dc.description.abstract","Background: Rare TREM2 variants are significant risk factors for Alzheimer's disease (AD). Methods: We used next generation sequencing of the whole gene (n = 700), exon 2 Sanger sequencing (n = 2634), p.R47H genotyping (n = 3518), and genome wide association study imputation (n = 13,048) to determine whether TREM2 variants are risk factors or phenotypic modifiers in patients with AD (n = 1002), frontotemporal dementia (n = 358), sporadic (n = 2500), and variant (n = 115) Creutzfeldt-Jakob disease (CJD). Results: We confirm only p.R47H as a risk factor for AD (odds ratio or OR = 2.19; 95% confidence interval or CI = 1.04-4.51; P =.03). p.R47H does not significantly alter risk for frontotemporal dementia (OR = 0.81), variant or sporadic CJD (OR = 1.06 95%CI = 0.66-1.69) in our cohorts. Individuals with p.R47H associated AD (n = 12) had significantly earlier symptom onset than individuals with no TREM2 variants (n = 551) (55.2 years vs. 61.7 years, P = .02). We note that heterozygous p.R47H AD is memory led and otherwise indistinguishable from \"typical\" sporadic AD. Conclusion: We find p.R47H is a risk factor for AD, but not frontotemporal dementia or prion disease. (C) 2014 The Alzheimer's Association. All rights reserved."],["dc.identifier.doi","10.1016/j.jalz.2014.05.1751"],["dc.identifier.isi","000345310800004"],["dc.identifier.pmid","25160042"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31839"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","1552-5279"],["dc.relation.issn","1552-5260"],["dc.title","R47H TREM2 variant increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]